Tachykinin receptors and tachykinin receptor antagoni

Autonomic and Autacoid Pharmacology 13, 23-93

DOI: 10.1111/j.1474-8673.1993.tb00396.x

Citation Report

#	Article	IF	CITATIONS
1	Conformationally restricted analogs of CP-99,994: synthesis of a spirocyclic amine. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2083-2086.	1.0	18
2	1,4-Diacylpiperazine-2-(S)-[(N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2707-2712.	1.0	11
4	Conserved HisVI-17of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P. FEBS Letters, 1993, 336, 506-510.	1.3	34
5	Contribution of NK1 and NK2 receptor activation to high threshold afferent fibre evoked ventral root responses in the rat spinal cord in vitro. Brain Research, 1993, 625, 100-108.	1.1	52
6	In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. European Journal of Pharmacology, 1993, 250, 403-413.	1.7	352
7	Amastatin interferes with the antagonist properties of MEN 10,208 in the rabbit pulmonary artery but not in the hamster trachea. European Journal of Pharmacology, 1993, 236, 31-37.	1.7	8
8	Identification of both NK ₁ and NK ₂ receptors in guineaâ€pig airways. British Journal of Pharmacology, 1993, 110, 693-700.	2.7	21
9	Tachykinin NK ₁ but not NK ₂ receptors mediate nonâ€cholinergic excitatory junction potentials in the circular muscle of guineaâ€pig colon. British Journal of Pharmacology, 1993, 110, 795-803.	2.7	41
10	Receptor subtypes or species homologues: relevance to drug discovery. Trends in Pharmacological Sciences, 1993, 14, 376-383.	4.0	92
11	Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regulatory Peptides, 1993, 46, 9-19.	1.9	58
12	Tachykinin NK-1 and NK-2 receptors in the circular muscle of the guinea-pig proximal colon. Regulatory Peptides, 1993, 46, 386-388.	1.9	1
13	The effects of NK-1 and NK-2 receptor antagonists on the capsaicin evoked synaptic response in the rat spinal cord in vitro. Regulatory Peptides, 1993, 46, 413-414.	1.9	7
14	Vasoactive peptides and characterization of their receptors. Regulatory Peptides, 1993, 45, 323-340.	1.9	9
15	MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists. Regulatory Peptides, 1993, 47, 151-158.	1.9	13
16	Patent Update: Neurokinin Receptor Antagonists. Current Opinion in Therapeutic Patents, 1993, 3, 1157-1172.	0.2	3
17	Injury-induced plasticity of spinal reflex activity: NK1 neurokinin receptor activation and enhanced A-and C-fiber mediated responses in the rat spinal cord in vitro. Journal of Neuroscience, 1994, 14, 3672-3687.	1.7	150
18	Spasmolytic Effect of the NK2-Receptor-Selective Antagonist MEN 10,627 in Rat Small Intestine. The Japanese Journal of Pharmacology, 1994, 65, 281-283.	1.2	2
19	Isolation and Charactrization of Neurokinin a Receptor cDNAs from Guinea-Pig Lung and Rabbit Pulmonary Artery. Journal of Receptors and Signal Transduction, 1994, 14, 399-421.	1.2	6

#	ARTICLE	IF	Citations
20	Structural comparison of NK2 receptor agonists and antagonists. Journal of Computer-Aided Molecular Design, 1994, 8, 341-344.	1.3	6
21	Application of \hat{I}^2 -lactams in the synthesis of substance P antagonists: Preparation of 2-azabicyclo[3.3.1]nonane ring systems. Tetrahedron Letters, 1994, 35, 4701-4704.	0.7	11
22	Acyclic NK1 antagonists: Replacements for the benzhydryl group Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2161-2164.	1.0	14
23	The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1679-1684.	1.0	30
24	Articulating a pharmacophore driven synthetic strategy: Discovery of a potent substance P antagonist. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1865-1868.	1.0	13
25	Rational design of high affinity tachykinin NK1 receptor antagonists. Bioorganic and Medicinal Chemistry, 1994, 2, 357-370.	1.4	40
26	Synergistic role of muscarinic acetylcholine and tachykinin NK-2 receptors in intestinal peristalsis. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 349, 194-201.	1.4	40
27	Nitric oxide induces acetylcholine-mediated contractions in the guinea-pig small intestine. Naunyn-Schmiedeberg's Archives of Pharmacology, 1994, 350, 582-4.	1.4	26
28	The vanilloid (capsaicin) receptor: Receptor types and species differences. General Pharmacology, 1994, 25, 223-243.	0.7	189
29	Characterisation of [1251][MePhe7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance. European Journal of Pharmacology, 1994, 269, 65-72.	2.7	32
30	Characterization of tachykinin mediated increases in [Ca2+]i in Chinese hamster ovary cells expressing human tachykinin NK3 receptors. European Journal of Pharmacology, 1994, 269, 73-78.	2.7	17
31	In vivo effects of neurokinin B on rat urinary bladder motility: Involvement of tachykinin NK1 and NK2 receptors. Neuropeptides, 1994, 27, 53-62.	0.9	19
32	NK1 and NK2 receptors are similar in man and rabbit. Neuropeptides, 1994, 26, 385-390.	0.9	6
33	The involvement of substance P and neurokinin-1 receptors in the responses of rat dorsal horn neurons to noxious but not to innocuous mechanical stimuli applied to the knee joint. Brain Research, 1994, 666, 207-215.	1.1	35
34	Tachykinin receptors involved in the contractile effect of the natural tachykinins in the rat gastric fundus. Autonomic and Autacoid Pharmacology, 1994, 14, 383-392.	0.7	15
35	Referral of muscle pain. APS Journal, 1994, 3, 1-9.	0.2	56
36	$(\hat{A}\pm)$ -CP-96,345, an NK1 receptor antagonist, has local anaesthetic-like effects in a mammalian sciatic nerve preparation. Regulatory Peptides, 1994, 52, 39-46.	1.9	15
37	Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. British Journal of Pharmacology, 1994, 113, 111-116.	2.7	50

#	ARTICLE	IF	CITATIONS
38	Localization of striatal and nigral tachykinin receptors in the rat. Brain Research, 1994, 646, 13-18.	1.1	47
39	Different Ca2+ influx pathways mediate tachykinin receptor-induced contraction in circular muscle of guinea-pig colon. European Journal of Pharmacology, 1994, 255, 9-15.	1.7	29
40	Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. European Journal of Pharmacology, 1994, 253, 245-252.	1.7	62
41	Tachykinins contract trachea from Fischer 344 rats by interaction with a tachykinin NK1 receptor. European Journal of Pharmacology, 1994, 271, 47-54.	1.7	15
42	Different mechanism of tachykinin NK2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon. European Journal of Pharmacology, 1994, 271, 111-119.	1.7	27
43	Pharmacological assessment of spantide II analogues. European Journal of Pharmacology, 1994, 260, 121-128.	1.7	8
44	Comparison of tachykinin NK1 receptors in human IM9 and U373 MG cells, using antagonist (FK888,) Tj ETQq0	0 0 rgBT /	Overlock 10 T
45	Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. European Journal of Pharmacology, 1994, 259, 129-135.	1.7	60
46	Tachykinin NK1 and NK2 receptors mediate atropine-resistant ileal circular muscle contractions evoked by capsaicin. European Journal of Pharmacology, 1994, 259, 187-193.	1.7	22
47	Effect of N ^G â€monomethylâ€Lâ€arginine on kininâ€induced vasodilation in the human forearm British Journal of Clinical Pharmacology, 1994, 38, 307-310.	1.1	56
48	Comparison of tachykinin NK ₁ and NK ₂ receptors in the circular muscle of the guineaâ€pig ileum and proximal colon. British Journal of Pharmacology, 1994, 112, 150-160.	2.7	67
49	Tachykinin NK ₁ and NK ₂ receptor antagonists and atropineâ€resistant ascending excitatory reflex to the circular muscle of the guineaâ€pig ileum. British Journal of Pharmacology, 1994, 112, 161-168.	2.7	35
50	Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. British Journal of Pharmacology, 1994, 112, 240-249.	2.7	54
51	Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization. British Journal of Pharmacology, 1994, 112, 250-256.	2.7	13
52	Typical and atypical NK $<$ sub $>$ 1 $<$ /sub $>$ tachykinin receptor characteristics in the rabbit isolated iris sphincter. British Journal of Pharmacology, 1994, 112, 985-991.	2.7	17
53	Cutaneous vasodilatation induced by nitric oxideâ€evoked stimulation of afferent nerves in the rat. British Journal of Pharmacology, 1994, 112, 1181-1187.	2.7	48
54	Nonâ€specific actions of the nonâ€peptide tachykinin receptor antagonists, CPâ€96, 345, RP 67580 and SR 48968, on neurotransmission. British Journal of Pharmacology, 1994, 111, 179-184.	2.7	37
55	Characterization of NK ₁ and NK ₂ tachykinin receptors in guineaâ€pig and rat bronchopulmonary and vascular systems. British Journal of Pharmacology, 1994, 111, 759-768.	2.7	29

#	ARTICLE	IF	CITATIONS
56	Investigation of the specificity of FK 888 as a tachykinin NK ₁ receptor antagonist. British Journal of Pharmacology, 1994, 111, 1342-1346.	2.7	20
57	Inhibition by SR140333 of NK ₁ tachykinin receptorâ€evoked, nitric oxideâ€dependent vasodilatation in the hamster cheek pouch microvasculature ⟨i⟩in vivo⟨/i⟩. British Journal of Pharmacology, 1994, 113, 522-526.	2.7	16
58	Effect of the tachykinin NK ₁ receptor antagonists, RP 67580 and SR 140333, on electricallyâ€evoked substance P release from rat spinal cord. British Journal of Pharmacology, 1994, 113, 635-641.	2.7	33
59	â€~Sensoryâ€efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea <i>in vitro</i> . British Journal of Pharmacology, 1994, 113, 1183-1190.	2.7	45
60	SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sciences, 1994, 56, PL27-PL32.	2.0	131
61	In vivo evidence for the activation of a septide-sensitive tachykinin receptor in guinea pig bronchoconstriction Life Sciences, 1994, 54, PL327-PL332.	2.0	4
62	Neurokinin receptor subtypes characterized by biological assays. Life Sciences, 1994, 54, 2035-2047.	2.0	57
63	In vitro characterizat of the non-peptide tachykinin NK1 and NK2-receptor antagonists, SR140333 and SR48968 in different rat and guinea-pig intestinal segments. Life Sciences, 1994, 56, 267-275.	2.0	47
64	Tachykinin induced regulation of excitatory amino acid responses in the rat spinal cord in vitro. Neuroscience Letters, 1994, 168, 185-188.	1.0	28
65	Specialization of tachykinin NK1 and NK2 receptors in producing fast and slow atropine-resistant neurotransmission to the circular muscle of the guinea-pig colon. Neuroscience, 1994, 63, 1137-1152.	1.1	46
66	Multiple types of tachykinin receptor mediate a slow excitation of rat spinal motoneurones in vitro. Neuroscience Letters, 1994, 165, 84-88.	1.0	27
67	Vascular bedâ€dependent roles of the peptide CGRP and nitric oxide in acidâ€evoked hyperaemia of the rat stomach Journal of Physiology, 1994, 480, 575-585.	1.3	31
68	Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology, 1994, 107, 94-102.	0.6	103
69	Spasmolytic Effect of the NK2-Receptor-Selective Antagonist MEN 10,627 in Rat Small Intestine The Japanese Journal of Pharmacology, 1994, 65, 281-283.	1.2	21
70	Capsaicin-Induced Bladder Hyperactivity in Normal Conscious Rats. Journal of Urology, 1994, 152, 525-530.	0.2	68
71	Heteroreceptor-mediated modulation of noradrenaline and acetylcholine release from peripheral nerves., 1995, 126, 265-412.		95
72	Chapter 11 Electrophysiology of neuropeptides in the sensory spinal cord. Progress in Brain Research, 1995, 104, 175-195.	0.9	17
73	Chapter 6 Tachykinin receptors in the spinal cord. Progress in Brain Research, 1995, 104, 93-108.	0.9	18

#	Article	IF	CITATIONS
74	Chapter 9 Spinal cord tachykinins in the micturition reflex. Progress in Brain Research, 1995, 104, 145-159.	0.9	7
75	Chapter 14 Peptidergic afferents: physiological aspects. Progress in Brain Research, 1995, 104, 255-269.	0.9	6
76	Chapter 20 Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Progress in Brain Research, 1995, 104, 349-365.	0.9	12
77	Peptide-based tachykinin NK2 receptor antagonists. Medicinal Research Reviews, 1995, 15, 139-155.	5.0	11
78	Synthesis and biological evaluation of novel NK-1 tachykinin receptor antagonists: The use of cycloalkyl amino acids as a template. Biopolymers, 1995, 36, 511-524.	1.2	13
79	Substance-P receptors in human primary neoplasms: Tumoral and vascular localization. International Journal of Cancer, 1995, 61, 786-792.	2.3	196
80	Cellular sites of expression of the neurokinin-1 receptor in the rat gastrointestinal tract. Journal of Comparative Neurology, 1995, 358, 531-540.	0.9	150
81	Spiro-piperidine non-peptide neurokinin-1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2671-2676.	1.0	10
82	The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology, 1995, 121, 186-191.	1.5	69
83	Inhibition by actinomycin D of neurogenic mouse ear oedema. Inflammation Research, 1995, 44, 125-130.	1.6	5
84	Involvement of substance P as a mediator in capsaicin-induced mouse ear oedema. Inflammation Research, 1995, 44, 470-474.	1.6	36
85	Effect of SR 142801 on nitric oxide-dependent and independent responses to tachykinin NK3 receptor agonists in isolated guinea-pig colon. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 512-9.	1.4	17
86	Conformational rigidity versus flexibility in a novel peptidic neurokinin A receptor antagonist. Journal of Peptide Science, 1995, 1, 236-240.	0.8	21
87	Effects of coexisting neurochemicals on the release of serotonin from the intermediate area of rat thoracic spinal cord. Synapse, 1995, 21, 319-323.	0.6	6
88	An NK1Receptor-dependent Component of the Slow Excitation Recorded Intracellularly from Rat Motoneurons Following Dorsal Root Stimulation. European Journal of Neuroscience, 1995, 7, 2409-2417.	1.2	24
89	Tachykinin NK1and NK2receptors mediate the non-cholinergic bronchospastic response to capsaicin and vagal stimulation in guinea-pigs. Autonomic and Autacoid Pharmacology, 1995, 15, 49-54.	0.7	13
90	Role of tachykinins as excitatory mediators of NANC contraction in the circular muscle of rat small intestine. Autonomic and Autacoid Pharmacology, 1995, 15, 335-350.	0.7	23
91	1,2,4-Triacylpiperidine substance p antagonists: Separation of affinities for the NK-1 receptor and the L-type calcium channel. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 599-604.	1.0	6

#	Article	IF	Citations
92	Quinuclidine-based NK1 antagonists, the role of the benzhydryl. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1261-1264.	1.0	13
93	Photoactivatable analogues of a Substance P non-peptidic antagonist, for probing the antagonist binding site of the NK1 receptor. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1271-1274.	1.0	7
94	1,2,3-Trisubstituted cyclohexyl substance P antagonists: significance of the ring nitrogen in piperidine-based NK-1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1345-1350.	1.0	11
95	The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1773-1778.	1.0	25
96	Effects of three $\hat{l}\pm 2$ -Adrenoceptor agonists, rilmenidine, UK 14304 and clonidine on bradykinin- and substance P-induced airway microvascular leakage in guinea-pigs. Neuropeptides, 1995, 28, 197-207.	0.9	8
97	Neurokinin A and substance P vary independently in different regions of rat sensory neurons. Neuropeptides, 1995, 28, 237-241.	0.9	8
98	Further evidence that tachykinin-induced contraction of human isolated bronchus is mediated only by NK2-receptors. Neuropeptides, 1995, 29, 281-292.	0.9	43
99	GR 73,632 and [Glu(OBzl)11]substance P are selective agonists for the septide-sensitive tachykinin NK1 receptor in the rat urinary bladder. Neuropeptides, 1995, 28, 99-106.	0.9	9
100	The mammalian tachykinin receptors. General Pharmacology, 1995, 26, 911-944.	0.7	467
101	Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist. European Journal of Pharmacology, 1995, 289, 439-446.	2.7	25
102	In vivo detection of immunoreactive neurokinin A release within rat substantia nigra and its dependency on a dopaminergic input. Brain Research, 1995, 679, 241-248.	1.1	6
103	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. Brain Research, 1995, 700, 115-120.	1.1	13
104	Nedocromil sodium and sodium cromoglycate inhibit plasma extravasation in the guinea-pig conjunctiva. Ocular Immunology and Inflammation, 1995, 3, 37-44.	1.0	2
105	Neurokinin receptors subserving airways secretion. Canadian Journal of Physiology and Pharmacology, 1995, 73, 932-939.	0.7	17
106	Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Canadian Journal of Physiology and Pharmacology, 1995, 73, 854-859.	0.7	43
107	New molecules in analgesia. British Journal of Anaesthesia, 1995, 75, 145-156.	1.5	42
108	Involvement of neurokinin receptors in the induction but not the maintenance of mechanical allodynia in rat flexor motoneurones Journal of Physiology, 1995, 486, 769-777.	1.3	95
109	Modulation of chemotropism in the developing spinal cord by substance P. Science, 1995, 267, 899-902.	6.0	54

#	Article	IF	Citations
110	Stress-Induced Murine Abortion Associated with Substance P-Dependent Alteration in Cytokines in Maternal Uterine Decidua1. Biology of Reproduction, 1995, 53, 814-819.	1.2	102
111	Characterization of neurogenic inflammation in the airways of two highly inbred rat strains American Journal of Respiratory and Critical Care Medicine, 1995, 152, 1796-1804.	2.5	27
112	Effects of RP 67580 on substance P-elicited responses and postsynaptic potentials of motoneurones of the rat isolated spinal cord. Peptides, 1995, 16, 357-359.	1.2	5
113	Metabolic stability of some tachykinin analogues to cell-surface peptidases: Roles for endopeptidase-24.11 and aminopeptidase N. Peptides, 1995, 16, 441-447.	1.2	5
114	Characterization and autoradiographic mapping of [3H]CP96,345, a nonpeptide selective NK1 receptor antagonist in guinea pig lung. Peptides, 1995, 16, 867-872.	1.2	12
115	Heterogeneity of neurokinin1 binding sites in porcine respiratory tract. Peptides, 1995, 16, 873-882.	1.2	4
116	Parallel bioassay of PG-SPI, an amphibian acidic SP-like peptide, mammalian basic substance P, and neurokinins A and B on in vitro and in vivo test systems. Peptides, 1995, 16, 609-614.	1.2	5
117	Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Progress in Neurobiology, 1995, 45, 1-98.	2.8	430
118	RP67580, a neurokinin1 receptor antagonist, decreased restraint stress-induced defecation in rat. Neuroscience Letters, 1995, 198, 103-106.	1.0	36
119	Demonstration of a â€~septideâ€sensitive' inflammatory response in rat skin. British Journal of Pharmacology, 1995, 116, 2170-2174.	2.7	13
120	Comparative behavioural profile of centrally administered tachykinin NK ₁ , NK ₂ and NK ₃ receptor agonists in the guineaâ€pig. British Journal of Pharmacology, 1995, 116, 2496-2502.	2.7	18
121	The pharmacology of GR203040, a novel, potent and selective nonâ€peptide tachykinin NK ₁ receptor antagonist. British Journal of Pharmacology, 1995, 116, 3149-3157.	2.7	73
122	Passive immunization with an anti-substance P antibody prevents substance P- and neurokinin A-induced bronchospasm in anesthetized guinea-pigs. Life Sciences, 1995, 57, 143-153.	2.0	2
123	Neuronal nk3-receptors in guinea-pig ileum and taenia caeci: in vitro characterization by their first non-peptide antagonist, sr142801. Life Sciences, 1995, 57, PL361-PL366.	2.0	21
124	GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors. European Journal of Pharmacology, 1995, 272, 241-248.	1.7	44
125	Antibronchospastic activity of MEN10,627, a novel tachykinin NK2 receptor antagonist, in guinea-pig airways. European Journal of Pharmacology, 1995, 273, 129-135.	1.7	23
126	Activity of SR 142801 at peripheral tachykinin receptors. European Journal of Pharmacology, 1995, 278, 17-25.	1.7	77
127	Tachykinin NK1 receptors mediate both vasoconstrictor and vasodilator responses in the rabbit isolated jugular vein. European Journal of Pharmacology, 1995, 283, 233-240.	1.7	10

#	Article	IF	CITATIONS
128	[3H][î²-Ala8]neurokinin A-(4–10): a novel, selective radioligand for the tachykinin NK2 receptor. European Journal of Pharmacology, 1995, 294, 239-245.	1.7	3
129	Hypothalamic Tachykinins Annals of the New York Academy of Sciences, 1995, 771, 204-218.	1.8	15
130	Roles of peptides in enteric neuromuscular transmission. Regulatory Peptides, 1995, 56, 101-120.	1.9	61
131	Tachykinin receptors in gastrointestinal motility. Regulatory Peptides, 1995, 57, 19-42.	1.9	51
132	Interleukin-6 production by U373 MG, a human astrocytoma cell line: different pathways involved in substance P and lipopolysaccharide activation. Journal of Neuroimmunology, 1995, 59, 155-163.	1.1	23
133	Tachykinin NK ₂ receptors further characterized in the lung with nonpeptide receptor antagonists. Canadian Journal of Physiology and Pharmacology, 1995, 73, 878-884.	0.7	14
134	Inflammatory mediators of pain. British Journal of Anaesthesia, 1995, 75, 125-131.	1.5	471
135	Neurokinin receptors subserving bronchoconstriction. Canadian Journal of Physiology and Pharmacology, 1995, 73, 923-926.	0.7	1
136	Design and structure of a novel Neurokinin A receptor antagonist cyclo(-Met1-Asp2-Trp3-Phe4-Dap5-Leu6-)cyclo(2β-5β). Journal of the Chemical Society Perkin Transactions II, 1995, , 987-993.	0.9	25
137	Evidence that tachykinin NK ₁ and NK ₂ receptors mediate nonâ€adrenergic noncholinergic excitation and contraction in the circular muscle of guineaâ€pig duodenum. British Journal of Pharmacology, 1995, 115, 237-246.	2.7	46
138	Effects of the tachykinin NK ₁ receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B. British Journal of Pharmacology, 1995, 114, 1310-1316.	2.7	29
139	Functional interaction between losartan and central tachykinin NK ₃ receptors in the conscious rat. British Journal of Pharmacology, 1995, 114, 1563-1570.	2.7	19
140	Neuronal tachykinin NK2 receptors mediate release of non-adrenergic non-cholinergic inhibitory transmitters in the circular muscle of guinea-pig colon. Neuroscience, 1995, 69, 643-650.	1.1	30
141	Tachykininergic tone in the spinal cord of the rabbit: Dependence on nociceptive input arising from invasive surgery. Neuroscience, 1995, 69, 241-248.	1.1	15
142	NK1-tachykinin receptors and prolonged, stimulus-evoked alterations in the excitability of withdrawal reflexes in the decerebrated and spinalized rabbit. Neuroscience, 1995, 66, 673-683.	1.1	7
143	Chapter 6 Neurogenic mechanisms and neuropeptides in chronic pain. Progress in Brain Research, 1996, 110, 85-94.	0.9	11
144	2-Phenyl-4-quinolinecarboxamides:  A Novel Class of Potent and Selective Non-Peptide Competitive Antagonists for the Human Neurokinin-3 Receptor. Journal of Medicinal Chemistry, 1996, 39, 2281-2284.	2.9	49
145	Chapter 1 From acute to chronic pain: mechanisms and hypotheses. Progress in Brain Research, 1996, 110, 3-15.	0.9	34

#	Article	IF	CITATIONS
146	Use of a Dipeptide Chemical Library in the Development of Non-Peptide Tachykinin NK3 Receptor Selective Antagonists. Journal of Medicinal Chemistry, 1996, 39, 1664-1675.	2.9	48
147	Functional evidence for NOâ€synthase activation by substance P through a mechanism not involving classical tachykinin receptors in guineaâ€pig ileum ⟨i⟩in vitro⟨/i⟩. British Journal of Pharmacology, 1996, 118, 1253-1261.	2.7	4
148	Evidence that tachykinin NK ₂ receptors modulate resting tone in the rat isolated small intestine. British Journal of Pharmacology, 1996, 118, 1262-1268.	2.7	12
149	Characterization of tachykinin receptors mediating plasma extravasation and vasodilatation in normal and acutely inflamed knee joints of the rat. British Journal of Pharmacology, 1996, 118, 2107-2114.	2.7	17
150	Inhibition of Ca ²⁺ â€sensitive K ⁺ currents in NG 108â€15 cells by substance P and related tachykinins. British Journal of Pharmacology, 1996, 119, 315-320.	2.7	9
151	Evidence that tachykinins relax the guineaâ€pig trachea <i>via</i> nitric oxide release and by stimulation of a septideâ€insensitive NK ₁ receptor. British Journal of Pharmacology, 1996, 117, 1270-1276.	2.7	29
152	Pharmacological evidence that NKâ€2 tachykinin receptors mediate hypotension in the guinea pig but not in the rat. Fundamental and Clinical Pharmacology, 1996, 10, 337-343.	1.0	7
153	Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin receptor stimulation. Neuroscience, 1996, 74, 403-414.	1.1	46
154	Tachykinins: receptor to effector. International Journal of Biochemistry and Cell Biology, 1996, 28, 721-738.	1.2	248
156	A review of the design, synthesis and biological activity of the bicyclic hexapeptide tachykinin NK2 antagonist MEN 10627. Regulatory Peptides, 1996, 65, 55-59.	1.9	16
157	Vasoconstrictive effects of native tachykinins in the rainbow trout, Oncorhynchus mykiss. Peptides, 1996, 17, 39-45.	1.2	22
158	In vitro and in vivo biological activities of PG-KII, a novel kassinin-like peptide from the skin of the Australian frog, Pseudophryne g \tilde{A}^{1} 4ntheri. Peptides, 1996, 17, 1003-1008.	1.2	14
159	Effect of niflumic acid on electromechanical coupling by tachykinin NK 1 receptor activation in rabbit colon. European Journal of Pharmacology, 1996, 303, 197-204.	1.7	8
160	Autoradiographic localization of tachykinin NK2 and NK1 receptors in the guinea-pig lung, using selective radioligands. European Journal of Pharmacology, 1996, 311, 177-186.	1.7	17
161	Aerosolized tachykinin antagonists inhibit pentamidineâ€induced bronchoconstriction in guinea pigs. Fundamental and Clinical Pharmacology, 1996, 10, 518-523.	1.0	1
162	Tachykinins and central respiratory activity: an in vitro study on the newborn rat. European Journal of Pharmacology, 1996, 314, 41-50.	1.7	45
163	Characterization of tachykinin NK2 receptor on dog proximal colon. Antagonism by MEN 10,627 and SR 48,968. European Journal of Pharmacology, 1996, 318, 419-424.	1.7	11
164	Peripheral effects of three novel non-peptide tachykinin NK1 receptor antagonists in the anaesthetized rat. European Journal of Pharmacology, 1996, 318, 377-385.	1.7	12

#	Article	IF	CITATIONS
165	Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides, 1996, 17, 1397-1403.	1.2	34
166	Autoradiographic mapping of pulmonary NK1 and NK2 tachykinin receptors and changes after repeated antigen challenge in guinea pigs. Peptides, 1996, 17, 1389-1395.	1.2	5
167	Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood, 1996, 88, 98-106.	0.6	77
168	Chapter 25. On the role of tachykinins and calcitonin gene-related peptide in the spinal mechanisms of nociception and in the induction and maintenance of inflammation-evoked hyperexcitability in spinal cord neurons (with special reference to nociception in joints). Progress in Brain Research, 1996, 113, 423-441.	0.9	31
169	Chapter 27. Plasticity of excitatory synaptic transmission in the spinal cord dorsal horn. Progress in Brain Research, 1996, 113, 463-506.	0.9	47
170	Chapter 12. Neurokinin Receptor Antagonists. Annual Reports in Medicinal Chemistry, 1996, 31, 111-120.	0.5	4
171	Modulation of gut substance P after whole-body irradiation. Digestive Diseases and Sciences, 1996, 41, 2070-2077.	1.1	30
172	What are the roles of substance p and neurokinin-1 receptors in the control of negative chronotropic or negative dromotropic vagal motoneurons? a physiological and ultrastructural analysis. Brain Research, 1996, 715, 197-207.	1.1	13
173	Distribution of neurokinin-2 receptors in the guinea-pig gastrointestinal tract. Cell and Tissue Research, 1996, 286, 281-292.	1.5	79
174	Glycosyl derivatives of NK2 tachykinin receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 367-372.	1.0	9
175	Characterisation of substance P-induced endocytosis of NK1 receptors on enteric neurons. Histochemistry and Cell Biology, 1996, 106, 563-571.	0.8	47
176	Effect of the tachykinin receptor antagonists, SR 140333, FK 888, and SR 142801, on capsaicin-induced mouse ear oedema. Inflammation Research, 1996, 45, 303-307.	1.6	15
177	Effect of the non-peptide blocker CP 96,345 on the cellular mechanism involved in the response to NK1 receptor stimulation in human skin fibroblasts. Neuropeptides, 1996, 30, 345-354.	0.9	8
178	Localisation of NK1 receptor immunoreactivity to neurons and interstitial cells of the guinea-pig gastrointestinal tract., 1996, 367, 342-351.		161
179	The neostriatal mosaic: Basis for the changing distribution of neurokinin-1 receptor immunoreactivity during development. Journal of Comparative Neurology, 1996, 376, 463-475.	0.9	18
180	Development of HPLC plasma assays for CAM 4515 and CAM 4750, two new nonpeptide tachykinin antagonists, and application to bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis, 1996, 14, 1709-1716.	1.4	2
181	A Non-peptidic photoactivatable antagonist for mapping the antagonist binding site of the tachykinin NK2 receptor. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 605-608.	1.0	4
182	Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 951-956.	1.0	38

#	Article	IF	CITATIONS
183	SAR of 2-benzyl-4-aminopiperidines: CGP 49823, an orally and centrally active non-peptide NK1 antagonist. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1623-1628.	1.0	34
184	A reliable and efficient synthesis of SR 142801. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2307-2310.	1.0	15
185	Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: Examples with cholecystokinin and tachykinins. Bioorganic and Medicinal Chemistry, 1996, 4, 1573-1576.	1.4	29
186	SAR of 2-benzyl-4-aminopiperidines NK1 antagonists. Part 21. synthesis of CGP 49823. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 3029-3034.	1.0	16
187	Synthesis and biological activity of tachykinin analogs containing the adamantane moiety. International Journal of Peptide Research and Therapeutics, 1996, 2, 307-313.	0.1	0
188	The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 353, 475-81.	1.4	39
189	Augmentation of neurally evoked cholinergic bronchoconstrictor responses by prejunctional NK ₂ receptors in the guineaâ€pig. Autonomic and Autacoid Pharmacology, 1996, 16, 41-48.	0.7	21
190	Effect of several bicyclic peptide and cyclic pseudopeptide tachykinin NK ₂ receptor antagonists in the human isolated urinary bladder. Autonomic and Autacoid Pharmacology, 1996, 16, 251-260.	0.7	5
191	Airway neuropeptides and neutral endopeptidase in asthma. Clinical and Experimental Allergy, 1996, 26, 491-493.	1.4	3
192	Absorption of Cam-2445, an NK1 Neurokinin Receptor Antagonist: In Vivo, In Situ, and In Vitro Evaluations. Journal of Pharmaceutical Sciences, 1996, 85, 253-257.	1.6	13
193	The Role of Spinal Neurokinin-2 Receptors in the Processing of Nociceptive Information from the Joint and in the Generation and Maintenance of Inflammation-evoked Hyperexcitability of Dorsal Horn Neurons in the Rat. European Journal of Neuroscience, 1996, 8, 249-260.	1.2	59
194	Evidence for Modulation of DoDamine-neuronal Function by Tachykinin NK3Receptor Stimulation in Gerbil Mesencephalic Cell Cultures. European Journal of Neuroscience, 1996, 8, 801-808.	1.2	28
195	Biochemical Pathogenesis of Myofascial Pain. Journal of Musculoskeletal Pain, 1996, 4, 145-162.	0.3	40
196	Novel pharmacological strategies for analgesia Annals of the Rheumatic Diseases, 1996, 55, 715-722.	0.5	11
197	Tachykinins, Neurotrophism and Neurodegenerative Diseases: A Critical Review on the Possible Role of Tachykinins in the Aetiology of CNS Diseases. Reviews in the Neurosciences, 1996, 7, 187-214.	1.4	30
198	Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Cardiovascular Research, 1996, 31, 467-479.	1.8	62
199	Antipsychotic drugs: recent developments and novel agents. Expert Opinion on Therapeutic Patents, 1997, 7, 353-369.	2.4	4
200	Neurokinin Receptor Antagonists. CNS Drugs, 1997, 8, 436-447.	2.7	20

#	Article	IF	CITATIONS
201	Structure-based design in drug discovery - the application of a peptoid drug design strategy for the development of non-peptide neuropeptide receptor ligands. Expert Opinion on Investigational Drugs, 1997, 6, 349-365.	1.9	6
202	Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 1. Identification of the 4-Quinolinecarboxamide Framework. Journal of Medicinal Chemistry, 1997, 40, 1794-1807.	2.9	87
203	Transglutaminase-synthesized spermine derivative of substance P recognizes rat portal vein neurokinin-3 receptors. Life Sciences, 1997, 60, 403-411.	2.0	15
204	Tachykinin receptors in the guinea-pig isolated oesophagus: a complex system. British Journal of Pharmacology, 1997, 120, 1021-1028.	2.7	9
205	Tachykinin Actions on Deep Dorsal Horn NeuronsIn Wm: An Electrophysiological and Morphological Study in the Immature Rat. European Journal of Neuroscience, 1997, 9, 1037-1046.	1.2	14
206	Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations. Gastroenterology, 1997, 112, 1714-1743.	0.6	252
207	The dual nature of the tachykinin NK1 receptor. Trends in Pharmacological Sciences, 1997, 18, 351-354.	4.0	166
208	The dual nature of the tachykinin NK1 receptor. Trends in Pharmacological Sciences, 1997, 18, 351-355.	4.0	164
209	The effects of tachykinins on inflammatory and immune cells. Regulatory Peptides, 1997, 70, 75-90.	1.9	270
210	Myositis-induced functional reorganisation of the rat dorsal horn: effects of spinal superfusion with antagonists to neurokinin and glutamate receptors. Pain, 1997, 69, 219-230.	2.0	62
211	Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience, 1997, 78, 745-757.	1.1	66
212	Sequential activation of the triple excitatory transmission to the circular muscle of guinea-pig colon. Neuroscience, 1997, 79, 263-274.	1.1	23
213	Tachykinin NK1 and NK2 receptors mediate non-adrenergic non-cholinergic excitatory neuromuscular transmission in the guinea-pig stomach. Neuroscience, 1997, 80, 625-634.	1.1	23
214	Functional expression of a novel human neurokinin-3 receptor homolog that binds [3H]senktide and [125I-MePhe7]neurokinin B, and is responsive to tachykinin peptide agonists. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 310-315.	3.3	61
215	Characterization of neurokinin-1 receptors in the submucosal plexus of guinea pig ileum. American Journal of Physiology - Renal Physiology, 1997, 273, G670-G678.	1.6	17
216	Cellular pathways mediating tachykinin-evoked secretomotor responses in guinea pig ileum. American Journal of Physiology - Renal Physiology, 1997, 273, G1127-G1134.	1.6	18
217	Electrophysiological Evidence That Neurokinin A Acts Via NK-1 Receptors in the Cat Dorsal Horn. European Journal of Neuroscience, 1997, 9, 1977-1985.	1.2	8
218	Tandem Michael addition and azanorbornane substance-P antagonists. Tetrahedron, 1997, 53, 11121-11140.	1.0	7

#	Article	IF	CITATIONS
219	Renal effects of intracerebroventricularly injected tachykinins in the conscious saline-loaded rat: receptor characterization. British Journal of Pharmacology, 1997, 120, 785-796.	2.7	15
220	Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat. British Journal of Pharmacology, 1997, 121, 165-170.	2.7	111
221	Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea. British Journal of Pharmacology, 1997, 121, 773-781.	2.7	13
222	Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct. British Journal of Pharmacology, 1997, 122, 1633-1638.	2.7	21
223	Profile of neuronal excitation following selective activation of the neurokinin-1 receptor in rat deep dorsal horn in vitro. Brain Research, 1997, 767, 55-63.	1.1	13
224	Tachykinins in the gut. Part I. Expression, release and motor function. , 1997, 73, 173-217.		303
225	The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation. Neuropeptides, 1997, 31, 537-563.	0.9	205
226	Effect of several bicyclic peptide and cyclic pseudopeptide tachykinin NK2 receptor antagonists in the human isolated ileum and colon. Neuropeptides, 1997, 31, 71-77.	0.9	7
227	Central and peripheral antiulcer and antisecretory effects of Ala5NKA(4–10), a tachykinin NK2 receptor agonist, in rats. Neuropeptides, 1997, 31, 399-402.	0.9	9
228	Tachykinin NK1 and NK2 receptors mediate non-adrenergic noncholinergic excitatory neuromuscular transmission in the human ileum. Neuropeptides, 1997, 31, 265-271.	0.9	25
229	Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonist. Neuropeptides, 1997, 31, 373-379.	0.9	9
230	Multiple-model evaluation of absorption of a tachykinin receptor antagonist. Advanced Drug Delivery Reviews, 1997, 23, 121-131.	6.6	3
231	Role of tachykinins in non-adrenergic non-cholinergic excitation in smooth muscles of the gastrointestinal tract. Neurophysiology, 1997, 27, 338-344.	0.2	0
232	Localisation of neurokinin 3 (NK3) receptor immunoreactivity in the rat gastrointestinal tract. Cell and Tissue Research, 1997, 289, 1-9.	1.5	84
233	Binding and in vitro modulation of human epidermal Langerhans cell functions by substance P. Archives of Dermatological Research, 1997, 289, 285-291.	1.1	44
234	Neurogenic inflammation in lung disease: Burnt out?. Inflammopharmacology, 1997, 5, 319-329.	1.9	9
235	NK1- and NK3-receptor mediated inhibition of 5-hydroxytryptamine release from the vascularly perfused small intestine of the guinea-pig. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 689-693.	1.4	10
236	Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2531-2536.	1.0	24

#	Article	IF	CITATIONS
237	Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology, 1997, 37, 133-152.	2.0	220
238	Synthetic strategies for the construction of enantiomeric azanoradamantanes. Tetrahedron, 1997, 53, 1-20.	1.0	12
239	NK1 receptor expression in the interstitial cells of Cajal and neurons and tachykinins distribution in rat ileum during development., 1997, 383, 153-162.		56
240	Peptidergic activation of locust dorsal unpaired median neurons: Depolarization induced by locustatachykinins may be mediated by cyclic AMP., 1997, 33, 297-315.		46
241	Functional characterization of substance P receptors on cultured human spinal cord astrocytes: Synergism of substance P with cytokines in inducing interleukin-6 and prostaglandin E2 production., 1997, 21, 183-193.		83
242	Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature, 1998, 392, 394-397.	13.7	719
243	Endogenous peptidergic modulation of perisynaptic Schwann cells at the frog neuromuscular junction. Journal of Physiology, 1998, 512, 197-209.	1.3	31
244	MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK 2 receptor antagonist. British Journal of Pharmacology, 1998, 123, 81-91.	2.7	105
245	Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat. British Journal of Pharmacology, 1998, 123, 259-268.	2.7	25
246	Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. British Journal of Pharmacology, 1998, 124, 83-92.	2.7	20
247	In vitro characterization of tachykinin NK2 -receptors modulating motor responses of human colonic muscle strips. British Journal of Pharmacology, 1998, 124, 1321-1327.	2.7	47
248	Impaired IL- $1\hat{l}^2$ -induced neutrophil accumulation in tachykinin NK1 receptor knockout mice. British Journal of Pharmacology, 1998, 124, 1013-1015.	2.7	52
249	Evidence that tachykinins are the main NANC excitatory neurotransmitters in the guinea-pig common bile duct. British Journal of Pharmacology, 1998, 124, 1703-1711.	2.7	21
250	NK-3 receptors mediate enhancement of substance P release from capsaicin-sensitive spinal cord afferent terminals. British Journal of Pharmacology, 1998, 125, 621-626.	2.7	25
251	Excitatory motor and electrical effects produced by tachykinins in the human and guinea-pig isolated ureter and guinea-pig renal pelvis. British Journal of Pharmacology, 1998, 125, 987-996.	2.7	33
252	Activation of the cloned human NK3 receptor in Chinese Hamster Ovary cells characterized by the cellular acidification response using the Cytosensor microphysiometer. British Journal of Pharmacology, 1998, 125, 761-766.	2.7	17
253	An investigation of tachykinin NK2 receptor subtypes in the rat. European Journal of Pharmacology, 1998, 352, 103-109.	1.7	11
254	The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides, 1998, 32, 1-49.	0.9	274

#	Article	IF	CITATIONS
255	Stability of a constrained peptide-based antagonist of neurokinin A, as described by ab initio, semiempirical and empirical calculations. Computational and Theoretical Chemistry, 1998, 426, 339-347.	1.5	2
256	A method to measure dual NK1/NK2-antagonist activity in dogs. Journal of Pharmacological and Toxicological Methods, 1998, 39, 97-101.	0.3	9
257	Movement of villi induces endocytosis of NK1 receptors in myenteric neurons from guinea-pig ileum. Cell and Tissue Research, 1998, 292, 37-45.	1.5	39
258	Independent coupling of the human tachykinin NK2 receptor to phospholipases C and A2 in transfected Chinese hamster ovary cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 395-403.	1.4	18
259	A novel super-potent neurokinin A receptor antagonist containing dehydroalanine. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1153-1156.	1.0	10
260	Neuronorm is a potent and water soluble neurokinin A receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1735-1740.	1.0	1
261	Conformational probes for elucidating the nature of substance P binding to the NK1 receptor: initial efforts to map the Phe7-Phe8 region. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1679-1682.	1.0	15
262	Expression and presence of septal neurokinin-2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat. European Journal of Neuroscience, 1998, 10, 2337-2345.	1.2	36
263	Role of kinin B 1 and B 2 receptors and mast cells in post intestinal infectionâ€induced hypersensitivity to distension. Neurogastroenterology and Motility, 1998, 10, 499-508.	1.6	33
264	Building a model of interaction at the NK-2 receptors: Polycondensed heterocycles containing the pyrimidoindole skeleton. European Journal of Medicinal Chemistry, 1998, 32, 973-985.	2.6	16
265	Development and application of sensitive HPLC assays for NK3 antagonists in rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 1998, 16, 1171-1178.	1.4	0
266	Characterization of Actions of Leucophaea Tachykinin-Related Peptides (LemTRPs) and Proctolin on Cockroach Hindgut Contractions. Peptides, 1998, 19, 445-458.	1.2	41
267	Transglutaminase-Synthesized \hat{I}^3 -(Glutamyl5) Spermidine Derivative of Substance P Is a Selective Tool for Neurokinin-2 Receptors Characterization. Peptides, 1998, 19, 683-690.	1.2	13
268	Role of Tachykinins in the Regulation of the Hypothalamo–Pituitary–Adrenal Axis. Peptides, 1998, 19, 949-968.	1.2	74
269	The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli. Neuroscience, 1998, 83, 1251-1260.	1.1	22
271	Comparative effects of nonpeptide tachykinin receptor antagonists on experimental gut inflammation in rats and guinea-pigs. Life Sciences, 1998, 63, 293-304.	2.0	51
272	Vasoactive peptides in the skin. Journal of the European Academy of Dermatology and Venereology, 1998, 11, S73.	1.3	9
273	Derivation of a Three-Dimensional Pharmacophore Model of Substance P Antagonists Bound to the Neurokinin-1 Receptor. Journal of Medicinal Chemistry, 1998, 41, 3609-3623.	2.9	50

#	Article	IF	CITATIONS
274	Characterization of [3H]MEN 11420, a Novel Glycosylated Peptide Antagonist Radioligand of the Tachykinin NK2Receptor. Biochemical and Biophysical Research Communications, 1998, 248, 78-82.	1.0	14
275	Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. European Journal of Pharmacology, 1998, 341, 201-209.	1.7	22
276	Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain. European Journal of Pharmacology, 1998, 344, 115-120.	1.7	23
277	Neuropeptides. Archives of Surgery, 1998, 133, 1107-16.	2.3	152
278	A substance P receptor antagonist (FK 888) modifies gut alterations induced by ionizing radiation. International Journal of Radiation Biology, 1998, 74, 625-632.	1.0	9
279	Neurokinin Receptor Antagonists. Progress in Medicinal Chemistry, 1998, 35, 57-81.	4.1	20
280	Tachykinin Receptor Assays. Current Protocols in Pharmacology, 1998, 1, 4.10.1.	4.0	0
281	\hat{l}^2 2-Adrenoceptor Agonist-Induced Upregulation of Tachykinin NK2Receptor Expression and Function in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 409-417.	1.4	27
282	New Developments in the Understanding of the Pathophysiology of Muscle Pain. Journal of Musculoskeletal Pain, 1999, 7, 13-24.	0.3	7
283	Immunohistochemical localization of neurokinin-1 receptor in the lumbar spinal cord of young rats: morphology and distribution. Somatosensory & Motor Research, 1999, 16, 361-368.	0.4	4
284	Extracts and Constituents of Hypericum Perforatum Inhibit the Binding of Various Ligands to Recombinant Receptors Expressed with the Semliki Forest Virus System. Journal of Receptor and Signal Transduction Research, 1999, 19, 59-74.	1.3	55
285	Major metabolites of substance P degraded by spinal synaptic membranes antagonize the behavioral response to substance P in rats. Journal of Pharmaceutical Sciences, 1999, 88, 1127-1132.	1.6	21
286	Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. British Journal of Cancer, 1999, 79, 236-243.	2.9	57
287	Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. British Journal of Pharmacology, 1999, 127, 717-728.	2.7	31
288	Characterization of the [125 I]-neurokinin A binding site in the circular muscle of human colon. British Journal of Pharmacology, 1999, 127, 1105-1110.	2.7	18
289	Molecular and pharmacological characterization of a functional tachykinin NK3 receptor cloned from the rabbit iris sphincter muscle. British Journal of Pharmacology, 1999, 128, 627-636.	2.7	8
290	Mediators in hyperpnea-induced bronchoconstriction of guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 597-602.	1.4	26
291	Neurons bearing NK 3 tachykinin receptors in the guinea-pig ileum revealed by specific binding of fluorescently labelled agonists. Histochemistry and Cell Biology, 1999, 112, 233-246.	0.8	49

#	Article	IF	CITATIONS
292	Thoracic vagus section distal to the recurrent laryngeal nerve reduces substance. Anatomy and Embryology, 1999, 200, 153-160.	1.5	11
293	Effects of tyrosine289phenylalanine mutation on binding and functional properties of the human tachykinin NK2 receptor stably expressed in Chinese hamster ovary cells. Biochemical Pharmacology, 1999, 57, 899-906.	2.0	11
294	The tachykinin NK1 receptor in the brain: pharmacology and putative functions. European Journal of Pharmacology, 1999, 375, 51-60.	1.7	182
295	Interleukin- $1\hat{l}^2$ -induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchi. European Journal of Pharmacology, 1999, 379, 87-95.	1.7	28
296	Effect of non-peptide tachykinin NK1 receptor antagonists on non-adrenergic, non-cholinergic neurogenic mucus secretion in ferret trachea. European Journal of Pharmacology, 1999, 384, 173-181.	1.7	15
297	Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists. Il Farmaco, 1999, 54, 364-374.	0.9	20
298	Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. European Journal of Immunology, 1999, 29, 3815-3825.	1.6	162
299	Receptors in interstitial cells of Cajal: Identification and possible physiological roles. Microscopy Research and Technique, 1999, 47, 325-335.	1.2	41
301	Substance P immunoreactive nerves and interstitial cells of Cajal in the rat and guinea-pig ileum. A histochemical and quantitative study. Neuroscience Letters, 1999, 268, 49-52.	1.0	27
302	Substance p receptor (neurokinin-1)-expressing neurons in lamina i of the spinal cord encode for the intensity of noxious stimulation: a c-fos study in rat. Neuroscience, 1999, 89, 17-28.	1.1	107
303	Expression of neurokinin-1 receptors on cultured dorsal root ganglion neurons from the adult rat. Neuroscience, 1999, 90, 677-684.	1.1	25
304	Tachykinin receptors are involved in the "local efferent―motor response to capsaicin in the guinea-pig small intestine and oesophagus. Neuroscience, 1999, 90, 221-228.	1.1	45
305	Internalization of the neurokinin 1 receptor in rat myenteric neurons. Neuroscience, 1999, 91, 353-362.	1.1	29
306	Neurokinin B- and substance P-like immunoreactivity are co-localized in enteric nerves of rat ileum. Regulatory Peptides, 1999, 80, 67-74.	1.9	12
307	Transglutaminase-mediated amine incorporation into substance P protects the peptide against proteolysis in vitro. Regulatory Peptides, 1999, 84, 75-80.	1.9	19
308	Spinal actions of GR73632, a novel tachykinin NK1 receptor agonist. Peptides, 1999, 20, 301-304.	1.2	12
309	Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412). Journal of Medicinal Chemistry, 1999, 42, 1053-1065.	2.9	67
310	Characterization of [3H]substance P binding sites in human skin. Journal of the European Academy of Dermatology and Venereology, 1999, 12, 6-10.	1.3	45

#	Article	IF	CITATIONS
311	Chapter 11. Current and Potential New Therapies for Chronic Obstructive Pulmonary Disease. Annual Reports in Medicinal Chemistry, 1999, 34, 111-120.	0.5	0
312	Characterization of Tachykinin Receptors. Current Protocols in Pharmacology, 1999, 4, 1.15.1.	4.0	0
313	Role of the neuroendocrine system in pathogenesis of gastroenteritis. Current Opinion in Infectious Diseases, 2000, 13, 523-529.	1.3	4
314	Distribution of fos-like immunoreactivity within the rat brain following intraventricular injection of the selective NK3 receptor agonist senktide. Journal of Comparative Neurology, 2000, 426, 413-428.	0.9	25
315	Characterization of substance P-membrane interaction by transferred nuclear Overhauser effect. Biopolymers, 2000, 54, 297-306.	1.2	22
316	Cellular and synaptic effect of substance P on neonatal phrenic motoneurons. European Journal of Neuroscience, 2000, 12, 126-138.	1.2	37
317	Involvement of tachykinin NK2 receptors in the modulation of spontaneous motility in rat proximal colon. Neurogastroenterology and Motility, 2000, 12, 459-466.	1.6	25
318	Effects Of Tachykinins On Uterine Smooth Muscle. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 922-927.	0.9	39
319	Effects Of Tachykinin Receptor Agonists And Antagonists On The Guinea-Pig Isolated Oesophagus. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 934-938.	0.9	6
320	Role of tachykinins in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 321-337.	2.7	187
321	Combined tachykinin receptor antagonist: synthesis and stereochemical structure–activity relationships of novel morpholine analogues. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1665-1668.	1.0	30
322	Role of nitric oxide and septide-insensitive NK1 receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs. British Journal of Pharmacology, 2000, 129, 915-920.	2.7	20
323	Neurokinin B- and specific tachykinin NK3 receptor agonists-induced airway hyperresponsiveness in the guinea-pig. British Journal of Pharmacology, 2000, 130, 49-56.	2.7	37
324	Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK2 receptors. British Journal of Pharmacology, 2000, 131, 1461-1467.	2.7	9
325	Effect of nepadutant at tachykinin NK2 receptors in human intestine and urinary bladder. European Journal of Pharmacology, 2000, 398, 389-397.	1.7	40
326	Role of substance P and tachykinin receptor antagonists in citric acid-induced cough in pigs. European Journal of Pharmacology, 2000, 408, 305-312.	1.7	37
327	Title is missing!. International Journal of Peptide Research and Therapeutics, 2000, 7, 269-279.	0.1	6
328	Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. British Journal of Cancer, 2000, 82, 480-487.	2.9	66

#	ARTICLE	IF	CITATIONS
329	Substance P and central respiratory activity: a comparative in vitro study in NK1 receptor knockout and wild-type mice. Pflugers Archiv European Journal of Physiology, 2000, 440, 446-451.	1.3	26
330	NK1, NK2 and NK3 tachykinin receptor localization and tachykinin distribution in the ileum of the mouse. Anatomy and Embryology, 2000, 202, 247-255.	1.5	47
331	Mediators and Oxygen Radicals in Hyperpnea-Induced Airway Constriction of Guinea Pigs. Lung, 2000, 178, 213-223.	1.4	4
332	Evidence That the Proposed Novel Human "Neurokinin-4―Receptor Is Pharmacologically Similar to the Human Neurokinin-3 Receptor but Is Not of Human Origin. Molecular Pharmacology, 2000, 58, 552-559.	1.0	10
333	Association between Kinin B1 Receptor Expression and Leukocyte Trafficking across Mouse Mesenteric Postcapillary Venules. Journal of Experimental Medicine, 2000, 192, 367-380.	4.2	106
334	Hormonal Variation of Rat Uterine Contractile Responsiveness to Selective Neurokinin Receptor Agonists 1. Biology of Reproduction, 2000, 62, 1661-1666.	1.2	22
335	Activation of neurokinin NK2 receptors by tachykinin peptides causes contraction of uterus in pregnant women near term. Molecular Human Reproduction, 2000, 6, 549-554.	1.3	24
336	Oral anti-hyperalgesic and anti-inflammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. Pain, 2000, 87, 253-263.	2.0	10
337	Pain control: breaking the circuit. Trends in Pharmacological Sciences, 2000, 21, 284-286.	4.0	15
338	Principles of tachykininergic co-transmission in the peripheral and enteric nervous system. Regulatory Peptides, 2000, 93, 53-64.	1.9	75
339	Co-distribution of NK2 tachykinin receptors and Substance P in nerve endings of guinea-pig ileum. Neuroscience Letters, 2000, 287, 71-75.	1.0	16
340	Topical acetyl salicylate and dipyrone attenuate neurogenic protein extravasation in rat skin in vivo. Neuroscience Letters, 2000, 290, 57-60.	1.0	8
341	Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship. Peptides, 2000, 21, 1587-1595.	1.2	25
342	Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis. Neuropharmacology, 2000, 39, 1422-1429.	2.0	24
343	NK3 receptor blockade prevents hyperalgesia and the associated spinal cord substance P release in monoarthritic rats. Neuropharmacology, 2000, 39, 141-149.	2.0	20
344	Discovery of Potent Cyclic Pseudopeptide Human Tachykinin NK-2 Receptor Antagonists. Journal of Medicinal Chemistry, 2000, 43, 4041-4044.	2.9	17
345	Substance P antagonists: novel agents in the treatment of depression. Expert Opinion on Investigational Drugs, 2000, 9, 1871-1875.	1.9	29
346	Conformationally Constrained Substance P Analogues:Â The Total Synthesis of a Constrained Peptidomimetic for the Phe7-Phe8Region. Journal of Organic Chemistry, 2000, 65, 2484-2493.	1.7	68

#	Article	IF	CITATIONS
347	The Pharmacology and Mechanisms of Action of Rizatriptan., 2000, 17, 141-161.		4
348	Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors. Endocrine Reviews, 2000, 21, 90-113.	8.9	1,114
349	ACTIVITY OF NONPEPTIDE TACHYKININ ANTAGONISTS ON NEUROKININ A INDUCED CONTRACTIONS IN DOG URINARY BLADDER. Journal of Urology, 2000, 163, 1971-1974.	0.2	6
350	Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat jejunum. Gastroenterology, 2000, 119, 1037-1044.	0.6	41
351	Utilization of an Intramolecular Hydrogen Bond To Increase the CNS Penetration of an NK1Receptor Antagonist. Journal of Medicinal Chemistry, 2001, 44, 2276-2285.	2.9	73
352	Tachykinins contribute to nerve-mediated contractions in the human esophagus. Gastroenterology, 2001, 120, 39-48.	0.6	30
353	Substance P and its transglutaminase-synthesized spermine derivative elicit yawning behavior via nitric oxide in rats. Peptides, 2001, 22, 1453-1457.	1.2	16
354	Evolution of vertebrate neuropeptides. Brain Research Bulletin, 2001, 55, 723-735.	1.4	91
355	Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regulatory Peptides, 2001, 99, 151-156.	1.9	33
356	Structure determination and by-product profile of the NK2 receptor antagonist nepadutant, a bicyclic glycopeptide. FEBS Letters, 2001, 491, 299-304.	1.3	5
357	Depression of Windup of Spinal Neurons in the Neonatal Rat Spinal Cord In Vitro by an NK3 Tachykinin Receptor Antagonist. Journal of Neurophysiology, 2001, 85, 1502-1511.	0.9	34
358	Neuronal Bursting Induced by NK3 Receptor Activation in the Neonatal Rat Spinal Cord In Vitro. Journal of Neurophysiology, 2001, 86, 2939-2950.	0.9	21
359	A Family of Depsi-peptide Fungal Metabolites, as Selective and Competitive Human Tachykinin Receptor (NK2) Antagonists. Fermentation, Isolation, PhysicQ-chemical Properties, and Biological Activity Journal of Antibiotics, 2001, 54, 125-135.	1.0	19
360	Substance P and substance P receptors in bone and gingival tissues. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 2001, 34, 77-85.	1.8	35
361	Synthesis of MEN11420, a glycosylated bicyclic peptide, by intramolecular double cyclization using a chloroimidazolinium coupling reagent. Tetrahedron, 2001, 57, 1749-1755.	1.0	7
362	Three-dimensional quantitative structure–activity relationship for several bioactive peptides searched by a convex hull–comparative molecular field analysis approach. Computers & Chemistry, 2001, 25, 489-498.	1.2	4
363	Design of non-peptide CCK2 and NK1 peptidomimetics using 1 -(2-nitrophenyl)thiosemicarbazide as a novel common scaffold. Bioorganic and Medicinal Chemistry Letters, 2001, 11 , 705-709.	1.0	2
364	The roles of the N-terminal portions of various tachykinins in promoting salivation. Oral Diseases, 2001, 7, 238-245.	1.5	1

#	Article	IF	CITATIONS
365	Conformation of the tripeptide Cbz-Pro-Leu-Trp-OBzl(CF3)2deduced from two-dimensional1H-NMR and conformational energy calculations is related to its affinity for NK1-receptor. Journal of Peptide Science, 2001, 7, 323-330.	0.8	10
366	Heterogeneous control of blood flow amongst different vascular beds. Medicinal Research Reviews, 2001, 21, 1-60.	5.0	159
367	Synthesis and radiosynthesis with a positron emitter of EP 00652218, a potent antagonist of NK1 receptor, and of a fluoro analog for in vivo evaluation of the substance P receptor by pet. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S283-S285.	0.5	4
368	Leukocytes and neurogenic inflammation. Inflammopharmacology, 2001, 9, 403-420.	1.9	5
369	The neurokinin-1 receptor antagonist RP 67580 reduces the sensitization of primary afferents by substance P in the rat. European Journal of Pain, 2001, 5, 69-79.	1.4	15
370	Local and target-derived actions of neurotrophins during peripheral nervous system development. Cellular and Molecular Life Sciences, 2001, 58, 1036-1044.	2.4	65
371	Molecular and pharmacological characterization of the murine tachykinin NK3 receptor. European Journal of Pharmacology, 2001, 413, 143-150.	1.7	13
372	Effect of a tachykinin NK2 receptor antagonist, nepadutant, on cardiovascular and gastrointestinal function in rats and dogs. European Journal of Pharmacology, 2001, 415, 61-71.	1.7	10
373	Immunologically induced histamine release from rat peritoneal mast cells is enhanced by low levels of substance P. European Journal of Pharmacology, 2001, 414, 295-303.	1.7	21
374	Tachykinin NK2 receptor mediates contraction and ion transport in rat colon by different mechanisms. European Journal of Pharmacology, 2001, 415, 277-283.	1.7	13
375	Direct evidence for the interaction of neurokinin A with the tachykinin NK1 receptor in tissue. European Journal of Pharmacology, 2001, 423, 143-147.	1.7	10
376	Peripheral tachykinin receptors as targets for new drugs. European Journal of Pharmacology, 2001, 429, 13-21.	1.7	70
377	The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor. Neuropeptides, 2001, 35, 24-31.	0.9	27
378	Differential roles of spinal neurokinin 1/2 receptors in development of persistent spontaneous nociception and hyperalgesia induced by subcutaneous bee venom injection in the conscious rat. Neuropeptides, 2001, 35, 32-44.	0.9	28
379	Pharmacology of MEN 11467: a potent new selective and orally-effective peptidomimetic tachykinin NK1 receptor antagonist. Neuropeptides, 2001, 35, 137-147.	0.9	7
380	Tachykinin receptor antagonists for asthma and COPD. Expert Opinion on Therapeutic Patents, 2001, 11, 1097-1121.	2.4	20
381	Peripheral Activity of a New NK1Receptor Antagonist TAK-637 in the Gastrointestinal Tract. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 1046-1052.	1.3	20
382	Nonpeptide Tachykinin Receptor Antagonists. III. SB 235375, a Low Central Nervous System-Penetrant, Potent and Selective Neurokinin-3 Receptor Antagonist, Inhibits Citric Acid-Induced Cough and Airways Hyper-reactivity in Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics, 2002, 300. 314-323.	1.3	87

#	Article	IF	CITATIONS
383	Tachykinins and airway microvascular leakage induced by HCl intra-oesophageal instillation. European Respiratory Journal, 2002, 20, 268-273.	3.1	40
384	Tachykinin NK1 Receptors Mediate Atropine-Resistant Net Aboral Propulsive Complexes in Porcine lleum. Scandinavian Journal of Gastroenterology, 2002, 37, 531-535.	0.6	6
385	Estrogen-Dependent Regulation of Neurokinin 3 Receptor-Mediated Uterine Contractility in the Rat1. Biology of Reproduction, 2002, 67, 1480-1487.	1.2	18
386	Monocyclic Human Tachykinin NK-2 Receptor Antagonists as Evolution of a Potent Bicyclic Antagonist:Â QSAR and Site-Directed Mutagenesis Studies. Journal of Medicinal Chemistry, 2002, 45, 3418-3429.	2.9	12
387	Neurokinin-1 and neurokinin-3 receptors are expressed in vagal efferent neurons that innervate different parts of the gastro-intestinal tract. Neuroscience, 2002, 110, 339-349.	1.1	13
388	The role of lateral septal NK1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. Behavioural Brain Research, 2002, 134, 411-415.	1.2	32
389	The neurokinin-2 receptor is not involved in the sensitization of primary afferents of the rat knee joint. Neuroscience Letters, 2002, 326, 113-116.	1.0	3
390	The Tachykinin Peptide Family. Pharmacological Reviews, 2002, 54, 285-322.	7.1	537
391	Temporal increase in the reactivity of pulmonary vasculature to substance P in chronically hypoxic rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R858-R864.	0.9	12
392	Substance P-evoked Cl ^{â^²} secretion in guinea pig distal colonic epithelia: interaction with PGE ₂ . American Journal of Physiology - Renal Physiology, 2002, 283, G347-G356.	1.6	17
393	Neurokinins Activate Local Glutamatergic Inputs to Serotonergic Neurons of the Dorsal Raphe Nucleus. Neuropsychopharmacology, 2002, 27, 329-340.	2.8	70
394	Substance P-induced activation of p42/44 mitogen-activated protein kinase associated with cell proliferation in human tracheal smooth muscle cells. Cellular Signalling, 2002, 14, 913-923.	1.7	33
395	Tachykinins and tachykinin receptors in bone. Microscopy Research and Technique, 2002, 58, 91-97.	1.2	42
397	Antagonism by NKP608 of substance P-induced plasma protein exudation in a novel preparation of perfused trachea in rats and guinea-pigs in vivo. Inflammation Research, 2002, 51, 317-323.	1.6	0
398	Analogs of Substanceâ€fP modified at the C-terminus which are both agonist and antagonist of the NK-1 receptor depending on the second messenger pathway. Chemical Biology and Drug Design, 2002, 59, 232-240.	1.2	25
399	Design, synthesis and biological activity of carbohydrate-Containing peptidomimetics as new ligands for the human tachykinin NK-2 receptor. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2263-2266.	1.0	14
400	Novel potent substance P and neurokinin A receptor antagonists. Conception, synthesis and biological evaluation of indolizine derivatives. Bioorganic and Medicinal Chemistry, 2002, 10, 2905-2912.	1.4	28
401	Modulation of somatostatin receptors, somatostatin content and Gi proteins by substance P in the rat frontoparietal cortex and hippocampus. Journal of Neurochemistry, 2002, 84, 145-156.	2.1	5

#	Article	IF	Citations
402	The guinea-pig oesophagus is a versatile in vitro preparation for pharmacological studies. Clinical and Experimental Pharmacology and Physiology, 2002, 29, 1047-1054.	0.9	5
403	Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. British Journal of Pharmacology, 2002, 135, 266-274.	2.7	98
404	Tachykinin NK1 and NK2 receptors mediate inhibitory vs excitatory motor responses in human isolated corpus cavernosum and spongiosum. British Journal of Pharmacology, 2002, 135, 1351-1354.	2.7	7
405	Synthesis of a Novel Class of Non-Peptide NK-2 Receptor Ligand, Derived from 1-Phenyl-3-pyrrol-1-ylindan-2-carboxamides. Bioorganic and Medicinal Chemistry, 2002, 10, 1043-1050.	1.4	22
406	Efficient Synthesis of NK1Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformationâ€. Journal of the American Chemical Society, 2003, 125, 2129-2135.	6.6	157
407	Cardiovascular and behavioural effects induced by naloxone-precipitated morphine withdrawal in rat: characterization with tachykinin antagonists. Neuropeptides, 2003, 37, 345-354.	0.9	12
408	Contribution of tachykinin receptor subtypes to micturition reflex in guinea pigs. European Journal of Pharmacology, 2003, 477, 253-259.	1.7	6
409	The role of the amino-terminal domain of tachykinins in neurokinin-1 receptor signaling and desensitization. Neuropeptides, 2003, 37, 30-35.	0.9	9
410	RNA interference prevents lipopolysaccharide-induced preprotachykinin gene expression. Toxicology and Applied Pharmacology, 2003, 193, 47-54.	1.3	3
411	Synthesis of 2-(4-Biphenylyl)quinoline-4-carboxylate and Carboxamide Analogs. New Human Neurokinin-3 (hNK-3) Receptor Antagonists. Archiv Der Pharmazie, 2003, 336, 165-174.	2.1	6
412	Application of LC–NMR for the study of the volatile metabolite of MK-0869, a substance P receptor antagonist. Journal of Pharmaceutical and Biomedical Analysis, 2003, 30, 1431-1440.	1.4	21
413	Synthesis and Biological Evaluation of Halogenated Naphthyridone Carboxamides as Potential Ligands for in Vivo Imaging Studies of Substance P Receptors. Bioconjugate Chemistry, 2003, 14, 629-641.	1.8	3
414	Stereoselective Preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK1/NK2 Receptor Antagonist. Journal of Medicinal Chemistry, 2003, 46, 3508-3513.	2.9	9
415	Tachykinins mediate non-adrenergic, non-cholinergic excitatory neurotransmission to the hamster ileum via NK1 and NK2 receptors. Life Sciences, 2003, 73, 1939-1951.	2.0	14
416	A tachykinin-like factor increases glutamate toxicity in rat cerebellar granule cells. Neuropharmacology, 2003, 44, 117-124.	2.0	15
417	Biologic activity of the tachykinins on lamb and sheep gallbladder. Peptides, 2003, 24, 543-551.	1.2	2
418	Diencephalic neurons producing melanin-concentrating hormone are influenced by local and multiple extra-hypothalamic tachykininergic projections through the neurokinin 3 receptor. Neuroscience, 2003, 119, 1113-1145.	1.1	27
419	Cellular localization and distribution of neurokinin-1 receptors in the rat stomach. Autonomic Neuroscience: Basic and Clinical, 2003, 104, 95-108.	1.4	12

#	Article	IF	CITATIONS
420	Novel pharmacological targets and progression of new antitussive drugs. Expert Opinion on Therapeutic Patents, 2003, 13, 1501-1512.	2.4	9
421	The Role of Substance P in the Cerebral Ischemia. International Journal of Immunopathology and Pharmacology, 2003, 16, 67-72.	1.0	34
422	Recent developments in the management of detrusor overactivity. Current Opinion in Urology, 2003, 13, 285-291.	0.9	44
423	Effects of Substance P on Mesenteric Lymphatic Contractility in the Rat. Lymphatic Research and Biology, 2004, 2, 2-10.	0.5	38
424	Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea. Gut, 2004, 53, 952-957.	6.1	74
425	Lithiation of Functionalized Fluoroquinolines:  Synthesis of Dihalo-2-phenylquinoline-4-carboxamides and in Vitro Evaluation as NK-3 Receptor Ligands for Medical Imaging Studies. Journal of Organic Chemistry, 2004, 69, 2622-2625.	1.7	13
426	Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. European Respiratory Journal, 2004, 23, 76-81.	3.1	63
427	Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK1 receptor antagonist. European Journal of Pharmacology, 2004, 484, 57-64.	1.7	27
428	Involvement of enhanced neurokinin NK3 receptor expression in the severe asthma guinea pig model. European Journal of Pharmacology, 2004, 498, 287-294.	1.7	21
429	Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. Journal of Neurochemistry, 2004, 89, 54-63.	2.1	60
430	The syntheses of [14C] and [13C2,15N3]aprepitant. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 837-846.	0.5	5
431	Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK receptor quantitation: ([F]SPA-RQ). Molecular Imaging and Biology, 2004, 6, 373-384.	1.3	44
432	Greater Involvement of Neurokinins Found in Guinea Pig Models of Severe Asthma Compared with Mild Asthma. International Archives of Allergy and Immunology, 2004, 134, 263-272.	0.9	14
433	Insertion of an Aspartic Acid Moiety into Cyclic Pseudopeptides:Â Synthesis and Biological Characterization of Potent Antagonists for the Human Tachykinin NK-2 Receptor. Journal of Medicinal Chemistry, 2004, 47, 6935-6947.	2.9	13
434	Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin. Peptides, 2004, 25, 1971-1975.	1.2	5
436	Generation of a new class of hNK2 receptor ligands using the †fragment approachâ€. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 585-588.	1.0	7
437	Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. European Journal of Pharmacology, 2005, 516, 104-111.	1.7	5
438	Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides, 2005, 39, 467-474.	0.9	6

#	ARTICLE	IF	CITATIONS
439	AMPA Receptors Are Modulated by Tachykinins in Rat Cerebellum Neurons. Journal of Neurophysiology, 2005, 94, 2484-2490.	0.9	9
440	Tachykinin neuropeptides in cerebellar granule neurons: an immunocytochemical study. European Journal of Histochemistry, 2005, 49, 87.	0.6	2
441	TRPV1 Gene Knockout Impairs Postischemic Recovery in Isolated Perfused Heart in Mice. Circulation, 2005, 112, 3617-3623.	1.6	209
442	New challenges in the study of the mammalian tachykinins. Peptides, 2005, 26, 1356-1368.	1.2	113
443	Selective and Combined Neurokinin Receptor Antagonists. Progress in Medicinal Chemistry, 2005, 43, 49-103.	4.1	9
444	Sleep disturbance induced by substance P in mice. Behavioural Brain Research, 2006, 167, 212-218.	1.2	70
445	The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthma. Pulmonary Pharmacology and Therapeutics, 2006, 19, 413-418.	1.1	29
446	Correlation between the Appearance of Neuropeptides in the Rat Trigeminal Ganglion and Reinnervation of the Healing Root Socket after Tooth Extraction. Acta Histochemica Et Cytochemica, 2006, 39, 69-77.	0.8	17
447	New monocyclic and acyclic hNK-2 antagonists retaining the \hat{l}^2 -turn feature. X-ray and molecular modelling studies. Acta Crystallographica Section B: Structural Science, 2006, 62, 889-896.	1.8	7
448	Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma. Clinical and Experimental Allergy, 2006, 36, 1153-1160.	1.4	17
449	Relationships between neurokinin receptor-expressing interstitial cells of Cajal and tachykininergic nerves in the gut. Journal of Cellular and Molecular Medicine, 2006, 10, 20-32.	1.6	49
450	Substance P and Neurokinin 1 receptor - expression is affected in the ileum of mice with mutation in the W locus. Journal of Cellular and Molecular Medicine, 2006, 10, 511-518.	1.6	13
451	Extending the understanding of sensory neuropeptides. European Journal of Pharmacology, 2006, 533, 171-181.	1.7	90
452	Depressed Contractile Responses to Neurokinin A in Idiopathic but not Neurogenic Overactive Human Detrusor Muscle. European Urology, 2006, 49, 510-518.	0.9	18
453	Immunolocalization of Full-length NK1 Tachykinin Receptors in Human Tumors. Journal of Histochemistry and Cytochemistry, 2006, 54, 1015-1020.	1.3	26
454	Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opinion on Investigational Drugs, 2006, 15, 1017-1037.	1.9	21
455	Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. Journal of Neurosurgery, 2007, 107, 593-599.	0.9	55
456	Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex. Molecular Pharmacology, 2007, 72, 1411-1418.	1.0	36

#	Article	lF	Citations
457	Developments in the pharmacotherapy of the overactive bladder. Current Opinion in Urology, 2007, 17, 223-230.	0.9	18
458	Predominant surface distribution of neurokinin-3 receptors in non-dopaminergic dendrites in the rat substantia nigra and ventral tegmental area. Neuroscience, 2007, 144, 1393-1408.	1.1	10
459	Role of VIP and Substance P in NANC Innervation in the Longitudinal Smooth Muscle of the Rat Jejunum—Influence of Extrinsic Denervation. Journal of Surgical Research, 2007, 141, 22-30.	0.8	26
460	Neuropeptides in hyperthermia. Progress in Brain Research, 2007, 162, 277-293.	0.9	7
461	Discovery of a New Series of Potent and Selective Linear Tachykinin NK2Receptor Antagonists. Journal of Medicinal Chemistry, 2007, 50, 4793-4807.	2.9	19
462	Analgesic, Anti-inflammatory, and Anti-pyretic Activity., 2007,, 983-1116.		6
463	Application of hydrolytic kinetic resolution (HKR) in the synthesisÂof bioactive compounds. Tetrahedron, 2007, 63, 2745-2785.	1.0	96
464	$\hat{l}_{\pm},\hat{l}_{\pm}$ -Cyclic aminoacids as useful scaffolds for the preparation of hNK2 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4841-4844.	1.0	12
465	Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors. Biochemical Pharmacology, 2007, 73, 259-269.	2.0	16
466	Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists. European Journal of Pharmacology, 2007, 577, 78-86.	1.7	10
467	Placental Neurokinin B mRNA Expression Increases at Preterm Labor. Placenta, 2007, 28, 1020-1023.	0.7	11
468	Neuropeptides modulate RANKL and OPG expression in human periodontal ligament cells. Orthodontic Waves, 2007, 66, 33-40.	0.2	4
469	Long-Term Effects of Extrinsic Denervation on VIP and Substance P Innervation in Circular Muscle of Rat Jejunum. Journal of Gastrointestinal Surgery, 2007, 11, 1339-1350.	0.9	8
470	Tachykinins and their functions in the gastrointestinal tract. Cellular and Molecular Life Sciences, 2008, 65, 295-311.	2.4	115
471	Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists. Bioorganic and Medicinal Chemistry, 2008, 16, 2156-2170.	1.4	23
472	Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4705-4707.	1.0	5
473	Effect of chronic, extrinsic denervation on functional NANC innervation with vasoactive intestinal polypeptide and substance P in longitudinal muscle of rat jejunum $<$ sup $>1sup>. Neurogastroenterology and Motility, 2008, 20, 243-252.$	1.6	10
474	Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses. European Journal of Pharmacology, 2008, 586, 306-312.	1.7	10

#	Article	IF	CITATIONS
475	Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. European Journal of Pharmacology, 2008, 596, 153-159.	1.7	13
476	Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice Oncology, 2008, 5, 32-43.	4.3	96
477	Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats. Neuroscience Research, 2008, 60, 162-169.	1.0	9
478	Effects of Ischemia on Tachykinin-Containing Nerves and Neurokinin Receptors in the Rabbit Bladder. Urology, 2008, 71, 979-983.	0.5	27
479	Novel anti-inflammatory treatments for asthma. Expert Review of Respiratory Medicine, 2008, 2, 617-629.	1.0	5
480	Expression and coupling of neurokinin receptor subtypes to inositol phosphate and calcium signaling pathways in human airway smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L523-L534.	1.3	29
481	Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood, 2008, 111, 605-612.	0.6	40
482	Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies., 2009,, 443-492.		1
483	Tachykinins and Neurogenic Inflammation at Visceral Level. NeuroImmune Biology, 2009, 8, 289-320.	0.2	2
484	Lung respiratory rhythm and pattern generation in the bullfrog: role of neurokinin-1 and î¼-opioid receptors. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2009, 179, 579-592.	0.7	15
485	Important roles of tachykinins in the development of allergic nasal hyperresponsiveness in guineaâ€pigs. Clinical and Experimental Allergy, 2009, 39, 138-146.	1.4	10
486	Tachykinin receptor antagonists in clinical trials. Expert Opinion on Investigational Drugs, 2009, 18, 1843-1864.	1.9	65
487	A flexible approach to the design of new potent substance P receptor ligands. Journal of Pharmacy and Pharmacology, 2010, 53, 929-934.	1.2	6
488	Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery. Cell Biology and Toxicology, 2010, 26, 43-55.	2.4	6
489	Modulation on C―and Nâ€Terminal Moieties of a Series of Potent and Selective Linear Tachykinin NK ₂ Receptor Antagonists. ChemMedChem, 2010, 5, 65-78.	1.6	10
490	Role of Tachykinins in Asthma and Allergic Disease. , 2010, , 177-192.		0
491	Muscle healing and nerve regeneration in a muscle contusion model in the rat. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 894-899.	3.4	21
492	Tachykinin Receptor Assays. Current Protocols in Pharmacology, 2010, 48, Unit 4.10.	4.0	1

#	Article	IF	Citations
493	Molecular Modeling of Neurokinin B and Tachykinin NK ₃ Receptor Complex. Journal of Chemical Information and Modeling, 2011, 51, 2932-2938.	2.5	22
494	Neurochemistry of Endogenous Antinociception. Advances in Neurobiology, 2011, , 417-535.	1.3	0
495	Design of Novel Neurokinin 1 Receptor Antagonists Based on Conformationally Constrained Aromatic Amino Acids and Discovery of a Potent Chimeric Opioid Agonist-Neurokinin 1 Receptor Antagonist. Journal of Medicinal Chemistry, 2011, 54, 2467-2476.	2.9	41
496	Substance P Activates Both Contractile and Inflammatory Pathways in Lymphatics Through the Neurokinin Receptors NK1R and NK3R. Microcirculation, 2011, 18, 24-35.	1.0	35
497	Neurokinin B activates the formation and bone resorption activity of rat osteoclasts. Neuropeptides, 2011, 45, 239-244.	0.9	5
498	Implication of Substance P in myocardial contractile function during ischemia in rats. Regulatory Peptides, 2011, 167, 185-191.	1.9	13
499	Effect of subchronic administration of tachykinin antagonists on response of guinea-pigs to mild and severe stress. Regulatory Peptides, 2011, 168, 59-68.	1.9	1
501	Design, structure–activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists. Bioorganic and Medicinal Chemistry, 2011, 19, 6430-6446.	1.4	4
502	Early development evaluation of AZD8081: a substrate for the NK receptors. Drug Development and Industrial Pharmacy, 2011, 37, 702-713.	0.9	7
503	Selective Nasal Allergen Provocation Induces Substance P–Mediated Bronchial Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 517-523.	1.4	40
504	Neurokinin receptor 3 peptide exacerbates 6â€hydroxydopamineâ€induced dopaminergic degeneration in rats through JNK pathway. Journal of Neurochemistry, 2012, 123, 417-427.	2.1	4
505	Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010). Expert Opinion on Therapeutic Patents, 2012, 22, 57-77.	2.4	12
506	Novel 3-phenylpiperidine-4-carboxamides as highly potent and orally long-acting neurokinin-1 receptor antagonists with reduced CYP3A induction. Bioorganic and Medicinal Chemistry, 2012, 20, 962-977.	1.4	1
507	Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. European Journal of Pharmacology, 2013, 720, 180-185.	1.7	3
508	Characterization of ibodutant at NK2 receptor in human colon. European Journal of Pharmacology, 2013, 702, 32-37.	1.7	7
509	Hemokinin-1 competitively inhibits substance P-induced stimulation of osteoclast formation and function. Neuropeptides, 2013, 47, 251-259.	0.9	14
511	Neurokinin B Activates Arcuate Kisspeptin Neurons Through Multiple Tachykinin Receptors in the Male Mouse. Endocrinology, 2013, 154, 2750-2760.	1.4	134
512	Influence of a neurokininâ€1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers. Neurogastroenterology and Motility, 2013, 25, e830-8.	1.6	5

#	ARTICLE	IF	CITATIONS
513	Substance P as a neuronal factor in the enteric nervous system of the porcine descending colon in physiological conditions and during selected pathogenic processes. BioFactors, 2013, 39, 542-551.	2.6	43
514	Pharmacological Properties of FK886, a New, Centrally Active Neurokinin-1 Receptor Antagonist. Biological and Pharmaceutical Bulletin, 2013, 36, 76-81.	0.6	3
515	Anti-inflammatory Activity., 2014,, 1-137.		0
516	Role of neurokinin 1 receptors in dextran sulfate-induced colitis: studies with gene-deleted mice and the selective receptor antagonist netupitant. Inflammation Research, 2014, 63, 399-409.	1.6	10
517	Substance P enhances the activation of AMPK and cellular lipid accumulation in 3T3-L1 cells in response to high levels of glucose. Molecular Medicine Reports, 2015, 12, 8048-8054.	1.1	9
518	Membraneâ€induced structure of novel human tachykinin hemokininâ€1 (h <scp>HK</scp> 1). Biopolymers, 2015, 103, 702-710.	1.2	9
519	<i>Autonomic & Autacoid Pharmacology </i> : past, present and future. Autonomic and Autacoid Pharmacology, 2015, 35, 45-45.	0.5	3
520	Oxidative stress and substance P mediate psychological stress-induced autophagy and delay of hair growth in mice. Archives of Dermatological Research, 2015, 307, 171-181.	1.1	27
521	Substance P stimulates proliferation of spinal neural stem cells in spinal cord injury via the mitogen-activated protein kinase signaling pathway. Spine Journal, 2015, 15, 2055-2065.	0.6	31
522	Solid State Investigation and Characterization of a Nepadutant Precursor: Polymorphic and Pseudopolymorphic Forms of MEN11282. Crystal Growth and Design, 2016, 16, 5294-5304.	1.4	13
523	Neuropeptides and ATP signaling in the trigeminal ganglion. Japanese Dental Science Review, 2017, 53, 117-124.	2.0	51
524	Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis. Journal of Immunology, 2017, 199, 1543-1552.	0.4	233
525	Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4 H -pyran core: Switch from antagonist to agonist effect by chemical modification. European Journal of Medicinal Chemistry, 2017, 138, 644-660.	2.6	24
526	Substance P Receptor in the Rat Heart and Regulation of Its Expression in Long-Term Diabetes. Frontiers in Physiology, 2018, 9, 918.	1.3	5
527	Salt formation improved the properties of a candidate drug during early formulation development. European Journal of Pharmaceutical Sciences, 2018, 120, 162-171.	1.9	12
528	Substance P and fibrotic diseases. Neuropeptides, 2019, 76, 101941.	0.9	14
529	Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere?., 2019, 196, 44-58.		15
530	The crystalline salt form of a selected candidate drug showed photo-, thermal- and humidity induced form transitions. European Journal of Pharmaceutical Sciences, 2019, 128, 128-136.	1.9	1

#	Article	IF	CITATIONS
531	Detection of neurokininâ€1 receptor by immunohistochemistry in canine mammary gland tumours. Veterinary Medicine and Science, 2020, 6, 958-964.	0.6	1
532	Local and Systemic Factors Drive Ectopic Osteogenesis in Regenerating Muscles of Spinal-Cord–Injured Mice in a Lesion-Level–Dependent Manner. Journal of Neurotrauma, 2021, 38, 2162-2175.	1.7	8
533	Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi8, Met(O2)11]-Substance P for Future Clinical Application: First Experiences. Pharmaceutics, 2021, 13, 1326.	2.0	3
534	The Role of Neuropeptides in Pathogenesis of Dry Eye. Journal of Clinical Medicine, 2021, 10, 4248.	1.0	12
535	Tachykinin NK2 antagonist for treatments of various disease states. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102865.	1.4	1
537	Analgesic, anti-inflammatory, and anti-pyretic activity 1., 2002, , 670-773.		10
538	Structure-Activity Relationships of Agonist and Antagonist Ligands. , 1994, , 329-365.		4
539	Pharmacological Characterization of Receptor Types. , 1994, , 367-393.		4
540	Evidence for Receptor Subtypes/Species Variants of Receptors. , 1994, , 395-470.		12
541	The Nomenclature of Tachykinin Receptors. Handbook of Experimental Pharmacology, 2004, , 121-139.	0.9	3
542	Tachykinin NK1 Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 173-218.	0.9	3
543	Tachykinin NK2 Receptor Antagonists. Handbook of Experimental Pharmacology, 2004, , 219-244.	0.9	2
544	Peripheral Mediators of Pain. Handbook of Experimental Pharmacology, 1997, , 21-41.	0.9	12
545	Tachykinin Receptors and their Antagonists. , 1994, , 217-230.		4
546	A New potent and highly selective, long lasting, peptide based Neurokinin A antagonist: Rational design of MEN 10627., 1994,, 487-489.		4
547	Characterisation of substance P-induced endocytosis of NK1 receptors on enteric neurons. Histochemistry and Cell Biology, 1996, 106, 563-571.	0.8	4
548	Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345 [corrected]. Journal of Biological Chemistry, 1994, 269, 23959-23964.	1.6	39
549	Design of non-peptide agonists and antagonists for neuropeptide receptors. Advances in Amino Acid Mimetics and Peptidomimetics, 1999, , 165-190.	0.3	4

#	Article	IF	Citations
550	Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Canadian Journal of Physiology and Pharmacology, 1997, 75, 612-21.	0.7	21
551	Tachykinins mediate noncholinergic excitatory neural responses in the circular muscle of rat proximal colon. Canadian Journal of Physiology and Pharmacology, 1998, 76, 684-9.	0.7	8
552	Inflammation in Asthma., 1999, , 19-54.		5
553	CARDIOVASCULAR RESPONSES TO SCYLIORHININ I AND II IN THE RAINBOW TROUT, ONCORHYNCHUS MYKISS, IN VIVO AND IN VITRO. Journal of Experimental Biology, 1994, 191, 155-166.	0.8	5
554	Two novel tachykinin-related peptides from the nervous system of the crab Cancer borealis Journal of Experimental Biology, 1997, 200, 2279-2294.	0.8	121
555	Species-specific action and distribution of tachykinin-related peptides in the foregut of the cockroaches Leucophaea maderae and Periplaneta americana Journal of Experimental Biology, 1998, 201, 1615-1626.	0.8	31
556	The Role of Sonic Hedgehog Signaling in Osteoclastogenesis and Jaw Bone Destruction. PLoS ONE, 2016, 11, e0151731.	1.1	21
557	Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment. Oncotarget, 2017, 8, 40713-40723.	0.8	8
558	Neurokinin-1 Receptor Antagonists as Anticancer Drugs. Letters in Drug Design and Discovery, 2019, 16, 1110-1129.	0.4	6
559	Involvement of substance P and the NK-1 receptor in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 2321.	1.4	35
560	Localization of neurokinin B receptor in mouse gastrointestinal tract. World Journal of Gastroenterology, 2002, 8, 172.	1.4	11
561	Pharmacophore Pattern Identification of Tachykinin Receptor Selective Peptide Agonists: Implications in Receptor Selectivity. American Journal of Biochemistry and Biotechnology, 2007, 3, 180-186.	0.1	2
562	Tachykinins. , 2000, , 113-146.		0
564	Biological basis of anxiety and strategies for pharmacological innovation. , 2002, , 31-66.		0
565	Pre-protachykinin and Tachykinin Receptor Knockout Mice. Handbook of Experimental Pharmacology, 2004, , 297-340.	0.9	0
566	Substance P. , 2004, , 474-479.		0
567	Modulatory Role of NK1 Receptors in the Basal Ganglia. Studies in NK1-/- Mice., 2005,, 151-159.		0
570	Involvement of kinins and tachykinins in the development of nasal hyperresponsiveness in a guinea pig pollinosis model. Inflammation and Regeneration, 2010, 30, 524-530.	1.5	0

#	Article	IF	CITATIONS
571	Opioid System and Depression. , 2011, , 256-279.		1
572	Tachykinin Receptor Antagonists. Methods in Neurosciences, 1993, 13, 176-189.	0.5	0
573	Receptors for Vasoactive Peptides and their Implications in Physiopathology. Developments in Cardiovascular Medicine, 1994, , 387-401.	0.1	0
574	Structural requirements for antagonist activity at tachykinin NK2 receptor in a series of bicyclic hexapeptides., 1995,, 591-592.		1
576	Tachykinins and Calcitonin Gene-Related Peptide. , 1995, , 67-86.		0
577	Natural product peptidomimetics. Advances in Amino Acid Mimetics and Peptidomimetics, 1997, , 251-293.	0.3	1
578	Tachykinin receptors and the potential of tachykinin antagonists as clinically effective analgesics and anti-inflammatory agents. , 1999 , , $313-333$.		2
579	Tachykinin Receptor Antagonists. , 1999, , 203-235.		0
580	Anti-Inflammatory Activity. , 2016, , 1905-2024.		1
581	Tachykinin Receptor Antagonists. , 2017, , 275-299.		0
582	Changes in the expression of substance P in nerve fibres of the colonic mucosa in dogs suffering from inflammatory bowel disease. Acta Veterinaria Hungarica, 2020, 68, 154-159.	0.2	2
583	Biology of Neurotrophins, Neuropeptides, and Muscarinic Receptors in Asthma. , 2009, , 469-491.		0
584	Changes and Possible Role of Neuropeptides in latrogenic Dry Eye. Annals of Optometry and Contact Lens, 2022, 21, 8-14.	0.1	0
586	Influence of the Peripheral Nervous System on Murine Osteoporotic Fracture Healing and Fracture-Induced Hyperalgesia. International Journal of Molecular Sciences, 2023, 24, 510.	1.8	1
587	SYNTHESIS and STRUCTURE-ACTIVITY RELATIONSHIPS in PERHYDROISOINDOLE SUBSTANCE P ANTAGONISTS. European Journal of Medicinal Chemistry, 1995, 30, 575s-585s.	2.6	2
588	PEPTOID APPROACHES IN THE DESIGN OF ANTAGONISTS OF SUBSTANCE P AND CHOLECYSTOKININ. European Journal of Medicinal Chemistry, 1995, 30, 537s-550s.	2.6	0
589	The Activity of Substance P (SP) on the Corneal Epithelium. , 2023, 1, 35-51.		1